Columbus Venture Partners’ Post

I am thrilled to announce several critical milestones for Immuto: an oversubscribed, $8M fundraise, the realization of our target discovery and drug development platform, and an exciting collaboration with our valued colleagues at Daiichi Sankyo US. We're pleased to have this announcement covered by Boston Business Journal (https://lnkd.in/eCewZ-DP) and FirstWord Pharma (https://lnkd.in/eMENUXCz) Stepping into this next chapter for Immuto Scientific is about doing drug discovery differently. Armed with support from our visionary investors, we are leveraging our AI-enabled structural surfaceomics platform to find the hidden conformations of surface proteins that exist only in disease. By targeting these unique structures, we can develop therapies with unmatched precision. Additionally, working alongside our colleagues at Daiichi Sankyo US, we’re building strong momentum for what’s ahead. So proud to be a member of this team and I’m so excited for everyone to see what we do next.

What if targets were defined by structure, not just expression? That’s the door we’re opening: disease-specific conformations that legacy target ID couldn’t detect. At Immuto Scientific, we’re building a next-gen protein-folding AI grounded in high-resolution structural proteomics to infer in-cell conformational states. It powers our structural surfaceomics platform and enables rational design of antibodies against structural, disease-specific epitopes—targets that simply weren’t visible before. We’re now putting that engine to work with Daiichi Sankyo US in a discovery collaboration to identify cancer-specific surface targets and develop antibodies against them. Grateful to our team and investors for making this possible. #AIinBiotech #ProteinFolding #AntibodyDiscovery #DrugDiscovery

Exciting news from the team at Immuto Scientific! We just closed an $8M financing round and launched a drug discovery collaboration with Daiichi Sankyo US. At Immuto, we’re tackling one of the toughest challenges in drug discovery — finding truly novel, disease-specific targets. Using our AI-enabled structural surfaceomics platform, we uncover hidden protein structures that open the door to new therapies with greater precision and selectivity. With this support, we’re advancing our oncology pipeline, expanding into immunology and inflammation, and most importantly — working to bring life-changing therapies to patients. An exciting future path lies ahead as we push the boundaries of what’s possible in target discovery and drug development. Grateful to our amazing team, partners, and investors who share this vision. #DrugDiscovery #Oncology #Biotech #Immunology #AIinBiotech #ADCs #CancerResearch #Innovation #Startups #LifeChangingTherapies

We’re proud to share two major announcements. Immuto Scientific closed a new $8M financing round and launched a drug discovery collaboration with Daiichi Sankyo US to identify novel cancer-specific targets and develop new antibody-based therapies. The greatest challenge in drug discovery today is not a lack of modalities — it’s the shortage of truly novel, disease-specific targets. At Immuto Scientific, we are redefining target discovery with our AI-enabled structural surfaceomics platform, revealing cell-surface protein conformations invisible to conventional omics tools. These hidden structures open new therapeutic opportunities with exceptional precision and selectivity. With this new investment and alongside our partners, we’re propelling our internal oncology pipeline toward IND-enabling studies, expanding into immunology and inflammation and advancing our industry leading AI platform- built to unlock unprecedented insights into disease biology and reveal entirely new therapeutic targets. The financing was led by DYDX Capital with participation from new investors Gravity Fund and NVNG Investment Advisors, LLC and existing investors Great Oaks Venture Capital, WARF Ventures, among others. Read the release for more: https://lnkd.in/guKzprnN Learn more at www.immutotherapeutics.com #drugdiscovery #oncology #cancer #structuralsurfaceomics #targetdiscovery #ADCs #biotech #financing

Proud to announce two major milestones for Immuto Scientific! We’ve closed an oversubscribed $8M financing round and launched our first discovery collaboration with Daiichi Sankyo US to uncover novel surface targets in cancer. We’re pleased to welcome new investors DYDX Capital, Gravity Fund, and NVNG Investment Advisors, LLC to the team, and to deepen our partnership with the investors who have supported us from day one, including Great Oaks Venture Capital, Wisconsin Alumni Research Foundation (WARF) Ventures, and others. Over the last few years, our team has been working relentlessly to build cutting-edge platforms with unparalleled capabilities to uncover novel, disease-specific targets that were hiding in plain sight. That vision is now a reality. By revealing the hidden conformations of cell-surface proteins that define disease at a structural level, we’re expanding the target universe and opening doors to therapies with unprecedented precision and selectivity. We are advancing an internal pipeline of programs with first-in-class potential and collaborating with Daiichi Sankyo to expand into new areas. Together, we are illuminating what the field has long overlooked: the structural fingerprint of disease.   Thank you to our investors, our partners, and the Immuto team for making this vision real.

"Immuto Scientific creates and leverages data that no other group in the world has.” - Spencer M. of DYDX Capital Excited for this $8M round... but also the partnership with Daiichi Sankyo US, to discover new drug targets in solid tumors using its proprietary structural surfaceomics platform and to develop antibodies against these targets. In this funding round, Tundra Angels is thrilled to join up with Spencer M. of DYDX Capital, Adam G. of Gravity Fund, and continue the journey with Greg Keenan, Joshua J. Carson, Katie Rice, and Mike Partsch at Wisconsin Alumni Research Foundation (WARF) Ventures, Great Oaks Venture Capital, Brad Bodden Wisconsin Investment Partners, among others. Collectively, we're excited to be part of unlocking the new era of data‑driven drug discovery. 🚀

Grateful for the opportunity to speak at the 4th mRNA Process Development & CMC Summit in Boston! This meeting brought together an incredible community of drug developers committed to advancing the future of RNA medicines. It was a privilege to share some of Eclipsebio’s recent work during my talk on our eMERGE platform, and to learn from so many thoughtful discussions throughout the summit. A few themes that stood out: • Sequencing is expected to continue growing as a quality control method, offering deeper insights than traditional approaches. • Adapting QC thresholds designed for vaccines to new modalities such as gene editing and personalized cancer treatments is becoming a key challenge. • Collaboration between biopharmas, CDMOs, and CROs is essential. Several sessions highlighted the difficulties of doing everything in-house and the value of partnering for specialized expertise. Many thanks to the organizers, speakers, and attendees for creating such an engaging space. I’m leaving with new ideas and even greater respect for the collective effort it takes to bring RNA medicines to patients. #mRNA #RNAtherapeutics #CMC #ProcessDevelopment #Biotech #Eclipsebio

October brings exciting opportunities for ARTHEx Biotech to share our vision and connect with the biotech and investment community. Our Executive Chairman & CEO, Frederic LEGROS, will participate in multiple leading events focused on innovation in genetic medicines, including the Needham & Company Private Biotech and MedTech Forum, the Chardan/Sanofi Double Helix Den, and Chardan’s 9th Annual Genetic Medicines Conference. We’re proud to advance the ARTHEx mission: developing targeted RNA medicines — and to continue the dialogue on how precision RNA therapeutics can transform patient care for rare neuromuscular disorders and areas of high unmet need. Learn more: https://lnkd.in/grUQNPEF #ArthexBiotech #RNAtherapeutics #GeneticMedicine #BiotechInnovation

🚀 Big pharma money is on the move and small biotechs should be paying attention 🚀 Sanofi Ventures just raised $625M to fuel innovation in rare disease, neurology, immunology, and vaccines. For early-stage biotechs, this could mean survival and speed in a tough funding climate. It also means small companies will need sharper market access and pricing strategies earlier than ever. 👉 Will pharma VCs reshape the biotech funding landscape in 2026?